Dr. Joel W Neal, MDPHD is a Hematology / Oncology Specialist - General, Hematology / Oncology Specialist - Hematologist (Blood) practicing in Stanford, CA
He has not yet shared a personalized biography… Read more ›
| University | Degree | Focus | Graduated |
|---|---|---|---|
| Feinberg School of Medicine - Northwestern University | Medical Degree | 2004 |
| Institution | Focus | Year |
|---|---|---|
| Internship - Beth Israel Deaconess Medical Center | Not Specified | |
| Residency - Beth Israel Deaconess Medical Center | 2007 | |
| Fellowship - Dana-Farber Cancer Institute MA | 2010 | |
| Fellowship - Dana Farber Cancer Institute | 2010 |
| Certification | Cert. Body | Year |
|---|---|---|
Sub-Specialty: Medical Oncology | Internal Medicine | 2010 |
| Internal medicine | Internal Medicine | 2007 |
| Internal medicine | Internal Medicine | 2007 |
| Internal medicine Sub-Specialty: Medical Oncology | Internal Medicine | 2010 |
| Position | Organization | Time |
|---|---|---|
| Assistant Professor of Medicine (Oncology) | the Stanford University Medical Center | Present |
| Publication | Publisher | Title | Published |
|---|---|---|---|
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | A Patient With Aplastic Lymphoma Kise-Positive Non | 2013 |
| Other Publication | JOURL OF THORACIC ONCOLOGY | A Case Series of NSCLC Patients with Different Molecular Characteristics | 2013 |
| Other Publication | Jourl of thoracic oncology | Targeting fibroblast growth factor receptor | 2012 |
| Other Publication | JOURL OF THORACIC ONCOLOGY | A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer | 2012 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer | 2012 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Ipilimumab in Combition With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB | 2012 |
| Other Publication | CLINICS IN CHEST MEDICINE | Current Magement of Small Cell Lung Cancer | 2011 |
| Other Publication | JOURL OF THORACIC ONCOLOGY | Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer | 2011 |
| Other Publication | FUTURE ONCOLOGY | The SATURN trial: the value of maintence erlotinib in patients with non-small-cell lung cancer | 2010 |
| Other Publication | Jourl of thoracic oncology | Cetuximab monotherapy in patients with advanced non | 2010 |
| Other Publication | ture reviews. Clinical oncology | Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. | 2010 |
| Other Publication | Clinical advances in hematology & oncology : H&O | First-line use of EGFR tyrosine kise inhibitors in patients with NSCLC containing EGFR mutations. | 2010 |
| Other Publication | BLOOD | Induction of FucT-VII by the Ras/MAP kise cascade in Jurkat T cells | 2003 |
| Other Publication | JOURL OF BIOLOGICAL CHEMISTRY | A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts | 2003 |
| Other Publication | JOURL OF BIOLOGICAL CHEMISTRY | Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells | 2002 |
| Other Publication | JOURL OF BIOLOGICAL CHEMISTRY | Glycogen synthase kise-3 inhibits the D binding activity of NFATc | 2001 |
| Other Publication | JOURL OF BACTERIOLOGY | REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE | 1994 |
| Other Publication | Clinical lung cancer | A Case Series of Lengthy Progression-Free Survival With Pemetrexed | 2013 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | A Patient With Anaplastic Lymphoma Kinase-Positive Non | 2013 |
| Other Publication | JOURNAL OF THORACIC ONCOLOGY | A Case Series of NSCLC Patients with Different Molecular Characteristics | 2013 |
| Other Publication | EXPERT OPINION ON BIOLOGICAL THERAPY | Aflibercept in lung cancer | 2013 |
| Other Publication | Journal of thoracic oncology | Targeting fibroblast growth factor receptor | 2012 |
| Other Publication | JOURNAL OF THORACIC ONCOLOGY | A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer | 2012 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer | 2012 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB | 2012 |
| Other Publication | Biologics : targets & therapy | First-line treatment of EGFR-mutant non-small-cell lung cancer | 2012 |
| Other Publication | CLINICS IN CHEST MEDICINE | Current Management of Small Cell Lung Cancer | 2011 |
| Other Publication | JOURNAL OF THORACIC ONCOLOGY | Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer | 2011 |
| Other Publication | CLINICAL CANCER RESEARCH | One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer | 2011 |
| Other Publication | FUTURE ONCOLOGY | The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer | 2010 |
| Other Publication | Journal of thoracic oncology | Cetuximab monotherapy in patients with advanced non | 2010 |
| Other Publication | CURRENT OPINION IN MOLECULAR THERAPEUTICS | AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer | 2010 |
| Other Publication | CURRENT TREATMENT OPTIONS IN ONCOLOGY | Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh | 2010 |
| Other Publication | Nature reviews. Clinical oncology | Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. | 2010 |
| Other Publication | Clinical advances in hematology & oncology : H&O | First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. | 2010 |
| Other Publication | BLOOD | Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells | 2003 |
| Other Publication | JOURNAL OF BIOLOGICAL CHEMISTRY | A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts | 2003 |
| Other Publication | JOURNAL OF BIOLOGICAL CHEMISTRY | Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells | 2002 |
| Other Publication | JOURNAL OF BIOLOGICAL CHEMISTRY | Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc | 2001 |
| Other Publication | JOURNAL OF BACTERIOLOGY | REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE | 1994 |
Dr. Joel W Neal, MDPHD has not yet indicated the hospitals that he is affiliated with.
Accepts New Patients: Yes
Dr. Joel W Neal, MDPHD has not yet listed the medications that he commonly prescribes.
Dr. Joel W Neal, MDPHD has not yet added any information about his practice's billing policies and payment options.
